PITER: An ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy

Digestive and Liver Disease

Volumn 47, Issue 9, 2015, Pages 741-743

  Kondili, Loreta A ^a   Vella, Stefano ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; EDITORIAL; HEPATITIS C VIRUS; HUMAN; INCIDENCE; ITALY; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; VIRAL CLEARANCE; CLINICAL TRIAL; COHORT ANALYSIS; HEPATITIS C, CHRONIC; METHODOLOGY; MULTICENTER STUDY;

ANTIVIRAL AGENTS; COHORT STUDIES; HEPATITIS C, CHRONIC; HUMANS; ITALY; RESEARCH DESIGN;

EID: 84939261214     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.05.022     Document Type: Editorial

References (12)

1. Chung R.T., Baumert T.F. Curing chronic hepatitis C - the arc of a medical triumph. New England Journal of Medicine 2014, 370:1576-1578.
2. Lange C.M., Jacobson I.M., Rice C.M., et al. Emerging therapies for the treatment of hepatitis C. EMBO Molecular Medicine 2014, 6:4-15.
3. Thomas D.L. Global control of hepatitis C: where challenge meets opportunity. Nature Medicine 2013, 19:850-858.
4. American Association for the Study of Liver Disease Recommendations for testing, managing and treating 2015, Available at:. http://www.hcvguideliness.org/.
5. European Association for the Study of the Liver Recommendations on treatment of hepatitis C 2015, Available at:. http://www.easl.eu/.
6. Documento di Indirizzo dell'Associazione Italiana per lo Studio del Fegato per l'uso razionale di antivirali diretti di seconda generazione nelle categorie di pazienti affetti da epatite C cronica ammesse alla rimborsabilità in Italia. Available at: http://www.webaisf.org/.
7. Guadagnino V., Stroffolini T., Rapicetta M., et al. Prevalence, risk factors and genotype distribution of hepatitis C virus infection in the general population: a community based survey in Southern Italy. Hepatology 1997, 26:106-111.
8. Bellentani S., Pozzato G., Saccoccio G., et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999, 44:874-880.
9. Maio G., D'Argenio P., Stroffolini T., et al. Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a Southern Italian town. Journal of Hepatology 2000, 33:116-120.
10. When to start Consortium Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009, 373:1352-1363.
11. Ping L.H., Jabara C.B., Rodrigo A.G., et al. HIV-1 transmission during early antiretroviral therapy: evaluation of two HIV-1 transmission events in the HPTN 052 prevention study. PLOS ONE 2013, 8:e71557.
12. Vella S. Treatment as prevention unanswered questions and progress to date. Journal of the International AIDS Society 2014, 17:19521.